Morgan Stanley’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-334
Closed -$1.03K 8414
2025
Q4
$1.03K Sell
334
-943
-74% -$4.69K ﹤0.01% 7360
2025
Q3
$8.34K Sell
1,277
-887
-41% -$6.5K ﹤0.01% 6951
2025
Q2
$19.4K Buy
2,164
+852
+65% +$7.07K ﹤0.01% 6659
2025
Q1
$8.29K Sell
1,312
-3,018
-70% -$28.2K ﹤0.01% 6856
2024
Q4
$44.7K Sell
4,330
-8,718
-67% -$95.9K ﹤0.01% 6320
2024
Q3
$168K Sell
13,048
-3,187
-20% -$46.8K ﹤0.01% 5815
2024
Q2
$225K Buy
16,235
+14,947
+1,160% +$1.69M ﹤0.01% 5610
2024
Q1
$401K Buy
+1,288
New +$343K ﹤0.01% 5410
2023
Q3
Sell
-10
Closed -$2.1K 7672
2023
Q2
$2.1K Buy
+10
New +$1.39K ﹤0.01% 7184
2023
Q1
Hold
0
-$3 7788
2022
Q4
Hold
0
7847
2022
Q2
Sell
-162
Closed -$33K 7900
2022
Q1
$33K Sell
162
-27
-14% -$5.93K ﹤0.01% 6901
2021
Q4
$41K Sell
189
-414
-69% -$133K ﹤0.01% 6908
2021
Q3
$275K Sell
603
-1,105
-65% -$418K ﹤0.01% 5830
2021
Q2
$685K Sell
1,708
-436
-20% -$199K ﹤0.01% 5320
2021
Q1
$1.24M Buy
2,144
+1,860
+655% +$1.16M ﹤0.01% 4593
2020
Q4
$162K Buy
284
+270
+1,929% +$152K ﹤0.01% 5693
2020
Q3
$8K Sell
14
-18
-56% -$11.2K ﹤0.01% 6333
2020
Q2
$18K Buy
+32
New +$23.4K ﹤0.01% 6033

Other funds holding LYRA

Morgan Stanley's LYRA Position: Q1 2026 in Review

Morgan Stanley sold out of LYRA THERAPEUTICS INC (LYRA) in Q1 2026, closing a stake of 334 shares — an estimated $1.03K sold.

Morgan Stanley first reported a position in LYRA in Q2 2020 and held it in 17 quarters. The position peaked at $1.24M in Q1 2021. 1 fund tracked by Wall St. Rank holds LYRA as of Q1 2026.

  • Morgan Stanley reported no remaining LYRA THERAPEUTICS INC position as of Q1 2026 after selling out during the quarter.
  • Morgan Stanley sold 334 LYRA THERAPEUTICS INC shares in Q1 2026, an estimated $1.03K.
  • Morgan Stanley first reported a position in LYRA THERAPEUTICS INC in Q2 2020 and held it in 17 quarters.
  • Morgan Stanley's LYRA THERAPEUTICS INC position peaked at $1.24M in Q1 2021.
  • 1 fund tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.